

AD _____

GRANT NUMBER DAMD17-96-1-6274

TITLE: Molecular Interactions of Bcl-2 Family Members in Breast Cancer Cells

PRINCIPAL INVESTIGATOR: Gabriel Nunez, M.D.

CONTRACTING ORGANIZATION: University of Michigan
Ann Arbor, Michigan 48103-1274

REPORT DATE: September 1998

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**Reproduced From
Best Available Copy**

DTIC QUALITY INSPECTED 3

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 1998	3. REPORT TYPE AND DATES COVERED Annual (1 Sep 97 - 31 Aug 98)	
4. TITLE AND SUBTITLE Molecular Interactions of Bcl-2 Family Members in Breast Cancer Cells			5. FUNDING NUMBERS DAMD17-96-1-6274	
6. AUTHOR(S) Gabriel Nunez, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Michigan Ann Arbor, MI 48103-1274			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			19981229 106	
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) A major genetic event that occurs in the pathogenesis of breast carcinoma involves alterations in the Bcl-2 survival pathway. To determine the role of the Bcl-2 family in maintaining cancer cell viability, we constructed a recombinant adenovirus vector that expresses Bcl-x _s , a dominant inhibitor of these proteins. In the original proposal, we proposed studies to determine the mechanism involved in Bcl-x _s -mediated apoptosis, to characterize cellular proteins that interact with Bcl-x _s using biochemical and genetic approaches, and to use a transgenic model of Bcl-x _s expression in the breast to assess the requirement for Bcl-2/Bcl-x _L in the maintenance of normal breast epithelia and tumor growth. During the last two years, we have characterized the interaction of Bcl-x _s with Bcl-2 and Bcl-x _L and identified through a genetic screen, HRK, a novel protein that interacts with Bcl-2 and Bcl-x _L . Mutational analysis of Bcl-x _s revealed a conserved region of this protein that is important for interaction with Bcl-x _L and induction of apoptosis. Bcl-x _L and Bcl-x _s were found to associate with Apaf-1, a critical regulator of caspases and cell death, suggesting that Bcl-x _s might antagonize Bcl-x _L through Apaf-1.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 17	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

☒ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

☒ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

☒ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



PI - Signature

9/23/88

Date

TABLE OF CONTENTS

1. FRONT COVER	
2. STANDARD FORM (SF) 298	
3. FOREWORD	
4. INTRODUCTION	1
5. BODY	2
6. CONCLUSIONS	5
7. REFERENCES	6
8. APPENDIX	8

INTRODUCTION

Cancer is the result of multiple genetic events, including activation of oncogenes and inactivation of tumor suppressor genes. The protein products of the former are often mitogens, whereas the products of the latter suppress proliferation. It is becoming increasingly apparent that tumor suppressor genes like p53 function in part by activating an apoptotic death pathway. In addition, certain oncogenes such as *bcl-2* appear to contribute to tumor development primarily by promoting abnormal cell survival via an apoptosis inhibitory signal. Thus, disruption of the apoptosis pathway appears integral to many malignancies including breast cancer. Furthermore, treatment of cancer with chemotherapy or radiation therapy is limited by the emergence of tumor cells resistant to these therapies. This resistance limits our ability to successfully treat these neoplasms.

bcl-2, the first member of an evolutionarily conserved family of apoptosis regulatory genes, was initially isolated from the t(14; 18) chromosomal translocation found in human B-cell follicular lymphomas, and was subsequently shown to repress cell death triggered by a diverse array of stimuli (1-2). Several members of the family, including Bcl-2, Bcl-x_L, Bcl-w, Mcl-1, and A1/Bfl-1, share conserved regions termed Bcl-2 homology domain 1, 2, 3, and 4 (BH1, BH2, BH3, and BH4), and function by repressing apoptosis (1-4). In contrast, structurally related proteins, including Bax, Bak, Bad, Bik/Nbk, Bid, Hrk, Bim, and Bok/Mtd, activate apoptosis (5-11). Biochemical and functional analyses have revealed that these pro-apoptotic proteins require the conserved BH3 region to interact with Bcl-2/ Bcl-x_L, and activate apoptosis in transient assays (5-11). Moreover, NMR studies have demonstrated that the BH3 domain of Bak interacts with a hydrophobic cleft formed by the conserved BH3 and BH1 regions of Bcl-x_L (12). To date, all death-promoting Bcl-2-related proteins heterodimerize with Bcl-2, Bcl-x_L, or Mcl-1, suggesting that these molecules promote cell death at least in part by interacting with and antagonizing Bcl-2, Bcl-x_L, and Mcl-1 (5-11). The biochemical process by which pro-survival Bcl-2 family members regulate cell death is poorly understood. It has been proposed that pro-survival family members regulate apoptosis by maintaining the integrity of the mitochondria (13). In addition, these Bcl-2 family proteins have been proposed to regulate apoptosis via physical interactions with central caspases through adaptor molecules, such as Apaf-1 and CED-4 (14-15).

A major genetic event that occurs in the genesis and/or progression of breast carcinoma involves alterations in the pathway of apoptosis. In breast cancer, one of the most common abnormalities is deregulated expression of Bcl-2 or Bcl-x_L proteins. Up to 90% of cancers originating from breast overexpress Bcl-2 or Bcl-x_L (16-17). We hypothesize deregulated expression of these proteins plays a critical role in the maintenance of breast cancer cells and resistance of tumor cells to therapy-induced apoptosis. To determine the role of the Bcl-2 family of proteins in maintaining cancer cell viability, we constructed a recombinant adenovirus vector that expresses Bcl-x_S, a dominant inhibitor of Bcl-2 and Bcl-x_L. Even in the absence of an exogenous apoptotic signal, this recombinant virus specifically and efficiently activates apoptosis in human carcinoma cells arising from multiple organs including breast, colon, stomach and sympathetic nervous tissue (18). Based on these results, we hypothesize that apoptotic signals are constitutively expressed in proliferating cancer cells and perhaps in normal cells, although repressed by members of the Bcl-2 family of proteins. In this proposal, we proposed studies (i) to determine the mechanism involved in Bcl-x_S-mediated apoptosis using the *bcl-x_S* adenovirus

to dissect molecular interactions of the Bcl-2 regulatory pathway; and (ii) to characterize cellular proteins that interact with Bcl-x_S using biochemical and genetic approaches. The studies outlined in this proposal may provide novel insight into the apoptosis pathway and lead to alternative therapeutic strategies for the treatment of breast cancer and other malignancies.

BODY OF THE ANNUAL REPORT

Technical Objective #1: Further characterization of the interaction of Bcl-x_S with Bcl-2, Bcl-x_L and Bax in breast cancer cells.

Task 1.1: Determine whether Bcl-x_S associates with Bcl-x_L and/or Bcl-2 *in vivo*.

We presented evidence in the original proposal that MCF-7 breast tumor cells and primary breast carcinoma cells undergo apoptotic cell death after exposure to a *bcl-x_S* adenovirus vector. Our hypothesis was that inactivation of Bcl-2 or Bcl-x_L by Bcl-x_S unleashes endogenous death signals leading to execution of the apoptotic program. We proposed experiments to examine molecular interactions of the Bcl-2 family members following expression of Bcl-x_S protein, but prior to morphological/biochemical cell death, in order to define those interactions which may be created or destroyed as the apoptotic program is activated.

Although these experiments were originally done in *bcl-x_S* adenovirus infected cells, we have since used transiently transfected cancer cells for the characterization of protein-protein interactions. Doing so has allowed us to perform immunoprecipitations of epitope tagged Bcl-x_S, which were previously impossible with the untagged *bcl-x_S* adenovirus. This model system is similar to that of the *bcl-x_S* adenovirus in that cancer cells undergo apoptosis in response to transient transfection of both untagged and HA-epitope tagged Bcl-x_S. To determine if Bcl-x_S associates with Bcl-x_L or Bcl-2, sequential Immunoprecipitation/Western-blot analysis was done on lysates of cells transfected with Bcl-x_S-HA and Bcl-x_L-Flag or Bcl-2-Flag. Lysates were immunoprecipitated with either anti-Flag or anti-HA antibodies. Washed protein complexes were resolved by SDS-PAGE, transferred to nitrocellulose and immunoblotted with the reciprocal antibody. These experiments showed that Bcl-x_S interacts with both Bcl-x_L-Flag and Bcl-2 Flag, although perhaps more weakly than with Bcl-x_L (Fig. 1.)

In additional experiments, we have performed extensive mutagenesis of the Bcl-x_S protein to determine the regions of Bcl-x_S required for its interaction with Bcl-x_L and those involved in breast cancer cell killing. We have expressed the Bcl-x_S mutants in cells *in vivo* (Fig. 2a), and have analyzed these mutants for their ability to kill a variety of cancer cells in the transient transfection assay. Results of these studies have mapped the domain required for killing as the BH3 domain (amino acids 86-98) (Fig. 2b.) Interestingly, the broad range caspase inhibitor, viral p35, is able to completely inhibit Bcl-x_S killing, suggesting that Bcl-x_S kills through a caspase dependent mechanism. We are currently analyzing these mutants for their ability to bind Bcl-x_L, both *in vitro* in the yeast 2-hybrid system, and *in vivo* in transiently transfected cancer cells.

Task 1.2: Determine whether Bcl-x_S disrupts the interaction of Bcl-x_L with Bax and Bak

We determined next if Bcl-x_S expression could alter the interaction of Bcl-x_L with BAX in transiently transfected cancer cells. In these experiments, FLAG-tagged Bcl-x_L/Bax complexes were immunoprecipitated with anti-FLAG in the presence or absence of Bcl-x_S, and the amount of bound endogenous BAX was determined by immunoblotting with anti-BAX antibody. The results showed that Bcl-x_S is unable to displace BAX from Bcl-x_L, even in cells that undergo Bcl-x_S mediated cell death (Fig. 3.) We could not determine if Bcl-x_S could alter Bcl-x_L binding to BAK, because the cancer cell lines we tested did not express detectable levels of endogenous BAK.

Task 1.3: Determine whether Bcl-XS functions by association with other proteins that regulate apoptosis

Recent experiments with nematode CED-9, CED-4 and CED-3 have suggested that Bcl-2 and Bcl-x_L regulate apoptosis by interacting with and inhibiting caspases (death proteases) through Apaf-1, a mammalian homologue of the *C. Elegans* CED-4 protein (14-15). These observations suggested that Bcl-x_S might antagonize Bcl-x_L by interfering with the ability of Bcl-x_L to inactivate the caspase regulator Apaf-1. We performed experiments to test whether Bcl-x_L could associate with Apaf-1 or procaspase-9, a central death protease that associates with Apaf-1 (19). The completion of these experiments with Bcl-x_L was important prior to the analysis of Bcl-x_S function. The analysis showed that Bcl-x_L and caspase-9 co-immunoprecipitated *in vivo* (Fig. 4a). As the nematode CED-9 protein, a homolog of mammalian Bcl-x_L, interacts with CED-3 through CED-4 (20-23), we determined if Bcl-x_L could associate with Apaf-1. Immunoblotting of Bcl-x_L complexes with anti-Myc antibody revealed that Apaf-1 co-immunoprecipitated with Bcl-x_L (Fig. 4b). To verify these results, we performed reciprocal experiments in which wt Apaf-1 and Apaf-1 deletion mutants were immunoprecipitated with anti-Myc antibody. Immunoblotting with anti-Flag confirmed that Bcl-x_L co-immunoprecipitated with Apaf-1 and revealed that Bcl-x_L associates with both the CED-4-like domain and the C-terminal region that contains the WD repeats of Apaf-1 (Fig. 4c).

These observations suggest that Bcl-2/Bcl-x_L control apoptosis at least in part through physical association with Apaf-1, and that Bcl-x_S might promote apoptosis by interfering with the ability of Bcl-x_L to associate with Apaf-1. We tested first whether Bcl-x_S was capable of interacting with Apaf-1. The analysis showed that Bcl-x_S co-immunoprecipitated with Apaf-1 (Fig. 5). This result indicates that regions outside the BH1-2 domains that are present in Bcl-x_S may mediate contact with Apaf-1. These preliminary results suggest that Bcl-x_S may promote apoptosis by competing with Bcl-x_L for Apaf-1 binding. Alternatively, the cellular interaction we have observed between Apaf-1 and Bcl-x_S might be indirect and mediated by binding of Bcl-x_S to endogenous Bcl-x_L or another adaptor protein. Future experiments to be conducted in the coming year will be performed to discriminate between these two models. These will include yeast two-hybrid analysis of the Bcl-x_S association with Apaf, and use of the Bcl-x_S deletion mutants to map region(s) required for this interaction.

Technical Objective #2: Further characterization and purification of p15, a cellular protein that interacts with Bcl-x_S.

A mechanism that might explain the apoptosis-promoting activity of Bcl-x_S is through binding to an upstream activator or a downstream effector of Bcl-2/Bcl-x_L mediated survival. In

preliminary results, we provided evidence in the original application that Bcl-x_S interacts with a cellular protein, p15, in cancer cells infected with the *bcl-x_S* adenovirus. The significance of the Bcl-x_S-p15 interaction was unclear. p15 could represent a death effector which is activated by the expression of Bcl-x_S. Alternatively, p15 could be a cellular protein required for survival whose activity is inhibited by the Bcl-x_S interaction. Clearly, biochemical characterization of p15 and isolation of the p15 cDNA was needed to further assess the role of p15 in Bcl-x_S-mediated apoptosis.

Task 2.1: Biochemical Purification and N-Terminal Microsequencing of p15

We purified p15 by virtue of its association not only with Bcl-x_S, but also with Bcl-2. Stably transfected Shep-1 neuroblastoma cells expressing Bcl-2 Flag were used as a source of the Bcl-2-associated p15 protein. We purified p15 isolated from preparative gels and submitted the material for microsequencing. The N-terminal sequence we obtained from the p15 material was: M/K-R-D-P-V-A-R-T-S. Except for the first amino acid, this sequence corresponds to amino acids of human Bcl-2 that are part of its flexible loop region (24). Two potential caspase cleavage sites occur within the loop at positions 34 and 64. However, the Bcl-2 fragment we sequenced failed to correspond to either caspase cleavage site. It is most likely the result of non-specific proteolysis of the exposed loop region, and is therefore a degradation product of Bcl-2. The original p15 protein identified as a Bcl-x_S binding protein is clearly different from the p15 we observed as a Bcl-2 associated band. However, we have been unable to detect any 15 kDa protein associating with Bcl-x_S-HA in variety of cancer lines tested. As the original p15 was detected in adenovirus Bcl-x_S-infected cells, it is possible that the p15 was an adenoviral gene product. Given these results we are no longer pursuing the characterization of the protein band termed p15.

Task 2.2: Genetic Screen for Bcl-x-Binding Proteins using the Two-Hybrid Yeast Assay

To search for Bcl-x-interacting proteins, we screened placenta and brain cDNA libraries using Gal4-Bcl-x_L and Gal4-Bcl-x_S as "baits" in the yeast two-hybrid assay. In the first screen using the GAL4-Bcl-x_L bait, fifty-six positive clones were identified that interacted with Gal4-Bcl-x_L. Forty-one cDNAs encoded Bad, a Bcl-2 family member recently isolated by binding to Bcl-2. Ten cDNAs encoded Bcl-2, which is known to bind Bcl-x_L in the two-hybrid system. The nucleotide sequences of four cDNAs were novel in that they did not reveal significant homology to any known gene or translated products in the databases. Three of these novel cDNAs encoded the same gene, which we have named *harakiri*. The same gene was identified as an interacting partner of Bcl-2. *Harakiri* functions as a regulator of Bcl-2 and Bcl-x_L and apoptotic cell death in mammalian cells. The *hrk* product (HRK) does not exhibit significant homology to Bcl-2 or Bcl-x_L and lacks the conserved BH1 and BH2 domains that are shared by Bcl-2 family members. Significantly, HRK physically interacts with anti-apoptosis proteins Bcl-2 and Bcl-x_L but not with death-promoting Bcl-2 members such as Bax and Bak. Expression of HRK induces rapid onset of cell death in mammalian cells including breast cancer cells. Importantly, the death-promoting activity of HRK is repressed by Bcl-2 and Bcl-x_L, suggesting that HRK is a common target of the anti-apoptosis proteins Bcl-2 and Bcl-x_L. Details of these results have been recently published (Inohara *et al.* The EMBO J. 16:1686-1694, 1997). Because analysis of HRK is beyond the statements of work, we are not pursuing the analysis of HRK with funds provided by this grant.

CONCLUSIONS

The studies that we have performed in the past year are important in that they have provided information regarding the mechanism by which the Bcl-x_S kills tumor cells. Bcl-x_S physically associated with Bcl-x_L and Bcl-2 in cancer cells although the binding to Bcl-x_L was stronger than with Bcl-2. Mutational analysis has revealed that the BH3 domain of Bcl-x_S is critical for Bcl-x_L binding and induction of apoptosis. Particularly revealing was the interaction of Bcl-x_L and Bcl-x_S with Apaf-1, a mammalian counterpart of nematode CED-4. These results suggest that Bcl-x_S promotes apoptosis by antagonizing Bcl-x_L through Apaf-1.

REFERENCES

1. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. *Nature*. 335:440-442 (1988).
2. Nuñez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. *J Immunol*. 144:3602-3610 (1990).
3. Boise LH, González-García M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G, Thompson CB. *bcl-x*, a *bcl-2* related gene that functions as a dominant regulator of apoptotic cell death. *Cell*. 74:597-608 (1993).
4. Zha H, Aime-Sempe C, Sato T, Reed JC. Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. *J Biol Chem*. 271:7440-7444 (1996).
5. Oltvai ZN, Millman CL, Korsmeyer SJ. Bcl-2 heterodimerizes *in vivo* with a conserved homolog, Bax, that accelerates programmed cell death. *Cell*. 74:609-619 (1993).
6. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-x_L and Bcl-2, displaces Bax and promotes cell death. *Cell*. 80:285-291 (1995).
7. Han J, Sabbatini P, White E. Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K. *Mol Cell Biol*. 16:5857-5864 (1996).
8. Wang K, Yin XM, Chao DT, Millman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. *Genes Dev*. 10:2859-2869 (1996).
9. Inohara N, Ding D, Chen S, Nuñez G. *harakiri*, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-x_L. *EMBO J*. 16:1686-1694 (1997).
10. Inohara N, Ekhterae D, García I, Carrio R, Merino J, Merry A, Chen S, Nuñez G. Mtd, a novel Bcl-2 family member activates apoptosis in the absence of heterodimerization with Bcl-2 and Bcl-x_L. *J Biol Chem*. 273(15):8705-8710 (1998).
11. Chittenden T, Flemington C, Houghton AB, Ebb RG, Gallo GJ, Elangovan B, Chinnadurai G, Lutz RJ. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. *EMBO J*. 14(22):5589-5596 (1995).
12. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW. Structure of Bcl-x_L-Bak peptide complex: recognition between regulators of apoptosis. *Science*. 275:983-986 (1997).
13. Vander Heider MG, Chandel NS, Williamson EK, Schumacker PT, Thompson CB. Bcl-x_L regulates the membrane potential and volume homeostasis of mitochondria. *Cell*. 91(5):627-637 (1997).
14. Pan G, O'Rourke K, Dixit VM. Caspase-9, Bcl-x_L, and Apaf-1 form a ternary complex. *J Biol Chem*. 273:5841-5845 (1998).
15. Hu Y, Benedict M, Wu D, Inohara N, Nuñez G. Bcl-x_L interacts with Apaf-1 and inhibits Apaf-1-dependent Caspase-9 activation. *Proc Natl Acad Sci USA*. 95:4386-4391 (1998).
16. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U. The Bcl-2 protein: a pronostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. *J Natl Cancer Inst*. 86:499-504 (1994).
17. Olopade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson CB, Recant WM. Overexpression of Bcl-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. *Cancer J*. 230-237, 1997.

18. Clarke MF, Apel IJ, Benedict MA, Eipers PJ, Sumantran V, González-García M, Doedens M., Fukunaga N, Davidson B, Dick JE, Minn AJ, Boise LH, Thompson CB, Wicha M, Núñez G. A recombinant *bcl-x_s* adenovirus selectively induces apoptosis in cancer cells, but not normal bone marrow cells. *Proc Natl Acad Sci USA*. 92:11024-11028 (1995).
19. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to *C. elegans*, CED-4, participates in cytochrome c-dependent activation of caspase-3. *Cell*. 90:405-413 (1997).
20. Wu D, Wallen HD, Nuñez G. Interaction and regulation of subcellular localization of CED-4 by CED-9. *Science*. 275:1126-1128 (1997).
21. Chinnaiyan AM, Chaudhary D, O'Rourke K, Koonin EV, Dixit VM. Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. *Nature*. 388:728-729 (1997).
22. Spector MS, Desnoyers S, Hoepfner DJ, Hengartner MO. Interaction between the *C. elegans* cell-death regulators CED-9 and CED-4. *Nature*. 385:653-656 (1997).
23. Wu D, Wallen, HD, Inohara N, Nuñez G. Interaction and regulation of the *C. Elegans* death protease CED-3 by CED-4 and CED-9. *J Biol Chem*. 274:21449-21454 (1997).
24. Chang BS, Minn AJ, Muchmore SW, Fesik SW, Thompson CB. Identification of a novel regulatory domain in Bcl-x_L and Bcl-2. *EMBO J*. 16(5):968-977 (1997).

APPENDIX

Figure 1





Figure 1 Bcl-xS-HA associates with both Bcl-XL-Flag and Bcl-2-Flag in cancer cells

Cancer cells were transiently transfected with Bcl-xs-HA and Bcl-xL-Flag or Bcl-2-Flag. Anti-Flag (A) or Anti-HA (B) complexes were immunoprecipitated and immunoblotted with the reciprocal antibody. The lower panels are immunoblots of transfected cell lysates.

Figure 2

A.



B.




Figure 2 Deletion Analysis of Bcl-xS

A. Anti-HA Western Blot of HA-Bcl-xs mutants transiently expressed in cancer cells.
 B. Transient transfection assay to measure Bcl-xs killing of cancer cells. Plasmids were co-transfected with pCMV Bgal; 18 hrs. post-transfection, cells were stained with X-gal and % blue cells with apoptotic morphology was measured.

Figure 3




Figure 3 Bcl-xs fails to disrupt Bax/Bcl-XL complexes

Cancer cells were transiently transfected with Bcl-xs-HA and/or Bcl-xL-Flag. Endogenous Bax/Bcl-xL complexes were immunoprecipitated with anti-Flag and immunoblotted with either anti-Bax, anti-HA or anti-Flag. The lower panels are anti-Bax and anti-HA immunoblots of transfected cell lysates.




FIGURE 4. Bcl-x_L interacts with caspase-9 and Apaf-1. (A) Bcl-x_L interacts with caspase-9. (Upper) Western blot analysis of immunoprecipitated Bcl-x_L and coimmunoprecipitated pro-caspase-9 and processed form (p35). (Lower) The expression of caspase-9 in total lysate. (B and C) Bcl-x_L interacts with Apaf-1. 293T cells were transfected with indicated plasmids and the lysates immunoprecipitated with anti-Flag (B) or anti-Myc (C) antibody. WT, full length Apaf-1-Myc; N, N-terminal Apaf-1-Myc; C, C-terminal Apaf-1-Myc. Panels show Western blot analysis of coimmunoprecipitated Apaf-1 and Bcl-x_L proteins. Asterisk indicates nonspecific band.

Figure 5




Figure 5 Bcl-xs-HA and Bcl-XL-Flag co-precipitate with Apaf-1 Myc

Cancer cells were transiently transfected with Apaf-1 Myc and Bcl-xs-HA or Bcl-xL-Flag. Apaf-1 complexes were immunoprecipitated with anti-Myc antibody and immunoblotted with anti-Flag, anti-HA, or anti-Myc. Lower panels are immunoblots of transfected cell lysates.